Printer Friendly

AGOURON PHARMACEUTICALS REPORTS THIRD QUARTER RESULTS

 AGOURON PHARMACEUTICALS REPORTS THIRD QUARTER RESULTS
 SAN DIEGO, May 1 /PRNewswire/ -- Agouron Pharmaceuticals Inc.


(NASDAQ/NMS: AGPH) today announced a net loss for the third quarter and nine months ended March 31, 1992, of $1,848,000, or $.27 per common share, and $6,435,000, or $1.08 per share, respectively. The net loss recorded in each comparable period of the prior fiscal year was $1,669,000, or $.35 per share, and $4,869,000, or $1.06 per share.
 Agouron Pharmaceuticals Inc. is a pioneer and leader in a new technology for the rational design of novel synthetic drugs based upon the molecular structures of proteins which play key roles in human disease. Agouron is currently applying this technology to the design and development of drugs for treatment of cancer, AIDS and other serious diseases.
 AGOURON PHARMACEUTICALS INC.
 Summary Financial Information
 (Dollars in thousands except per share amounts)
 Three months ended Nine months ended
 March 31, March 31,
 1992 1991 1992 1991
 Revenues $2,161 $1,146 $4,734 $3,592
 Net loss ($1,848) ($1,669) ($6,435) ($4,869)
 Net loss per
 common share ($.27) ($.35) ($1.08) ($1.06)
 Shares used in
 computing net loss
 per common share 6,865,000 4,837,000 5,965,000 4,608,000
 -0- 5/1/92
 /CONTACT: Steven S. Cowell, vice president and CFO, or Donna Nichols, manager of corporate communications of Agouron Pharmaceuticals, 619-622-3000/
 (AGPH) CO: Agouron Pharmaceuticals Inc. ST: California IN: MTC SU: ERN


CH-MC -- SD002 -- 5635 05/01/92 17:03 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 1, 1992
Words:259
Previous Article:WASHINGTON STATE REPUBLICAN CHAIRMAN SAYS DEMOCRATS SHOULD HOLD HEADS IN SHAME FOR RESISTING SUBPOENA OF HOUSE BANK RECORDS
Next Article:NEW DEALER FACILITY PART OF BUICK DESIGN PROGRAM


Related Articles
AGOURON PHARMACEUTICALS REPORTS FIRST QUARTER RESULTS
AGOURON PHARMACEUTICALS REPORTS SECOND QUARTER RESULTS
AGOURON PHARMACEUTICALS REPORTS FISCAL 1992 FINANCIAL RESULTS
AGOURON PHARMACEUTICALS REPORTS FIRST QUARTER RESULTS
AGOURON PHARMACEUTICALS REPORTS THIRD QUARTER RESULTS
AGOURON PHARMACEUTICALS REPORTS THIRD QUARTER RESULTS
AGOURON PHARMACEUTICALS REPORTS THIRD QUARTER RESULTS
AGOURON PHARMACEUTICALS REPORTS THIRD QUARTER RESULTS
AGOURON PHARMACEUTICALS REPORTS FISCAL 1995 FINANCIAL RESULTS
AGOURON PHARMACEUTICALS REPORTS THIRD QUARTER RESULTS

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters